ResApp share price explodes 50% on new Pfizer deal

rising medical asx share price represented by woman stretching happily in bedrising medical asx share price represented by woman stretching happily in bed

The ResApp Health Ltd (ASX: RAP) share price is leaping on news Pfizer has upped its bid for the company.

The biopharmaceutical giant has agreed to acquire the Brisbane-based health technology company for 20.8 cents per share. That’s up from its previous bid of 14.6 cents.

The ResApp share price is trading at 18 cents right now, 50% higher than its previous close.

However, that’s lower than its intraday high – and new 52-week high – of 19 cents.

Let’s take a closer look at the latest news from the takeover target.

ResApp share price takes off on upped takeover offer

The ResApp share price is soaring 50% on Wednesday after the company announced Pfizer has upped its takeover bid to 20.8 cents per share.

That sits within its assessed value range of 14.6 cents to 27.9 cents per ResApp share, as determined by an independent expert. It also values the company at around $179 million.

The pair have entered an amended scheme of arrangement agreement entailing the increased bid.

ResApp recommends shareholders vote in favour of the proposition in the absence of a superior proposal and subject to the independent expert continuing to conclude that the scheme is in investors’ best interests.

How did we get here?

ResApp is the developer of a smartphone app designed to detect COVID-19 using cough sounds.

The tech was recently dealt a blow when a data confirmation study returned significantly worse results than a previous pilot study.

Pfizer first put a takeover proposal to ResApp in April. Then, it offered just 11.5 cents per share.

That bid was upped to either 20.7 cents or 14.6 cents in June. Though, the higher of the bids was dependent on positive findings from the data confirmation study, which hadn’t been completed at the time.

Perhaps unsurprisingly, the ResApp share price plummeted 28.6% when the study’s disappointing results were released.

The post ResApp share price explodes 50% on new Pfizer deal appeared first on The Motley Fool Australia.

Should you invest $1,000 in Resapp Health right now?

Before you consider Resapp Health, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Resapp Health wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];[property] = defaultValue;

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);

More reading

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s